Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 23, 2017
Pharmacy Choice - Pharmaceutical News - Lupin launches Generic Minastrin 24 Fe chewable tablets in the US - June 23, 2017

Pharmacy News Article

 3/20/17 - Lupin launches Generic Minastrin 24 Fe chewable tablets in the US

Release date- 18032017 - Mumbai, Baltimore- Pharma Major Lupin Limited (Lupin) announced today the launch of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) is the AB rated generic equivalent of Allergan Pharmaceuticals International Limited's Minastrin 24 Fe Tablets. It is indicated for use by females of reproductive age to prevent pregnancy.

Minastrin 24 Fe chewable tablets had US sales of USD 360.5 million (IMS MAT December 2016).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5th and the 6th largest generics pharmaceutical company by market capitalization (December 31st, 2016, Bloomberg) and sales globally (September 30th, 2016, Bloomberg). The Company is the 5th largest pharmaceutical player in the US by prescriptions (4.68% market share - IMS Health, National Prescription Audit, March 2016); the 2nd largest Indian pharmaceutical company by revenues; the 6th largest generic pharmaceutical player in Japan and the 4th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31st March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact -

Arvind Bothra

Head - Investor Relations and M&A

Ph: +91-22-66402137

Email: arvindbothra@lupin.com

*Safe Harbor Statement

Minastrin is a registered trademark of Allergan Pharmaceuticals International Limited.



(c) 2017 Electronic News Publishing -

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jun 25: Legal & Practical Issues in Compounding Pharmacy
Jun 26: Drug Diversion & the Law: Considerations for Pharmacists & Technicians
Jun 27: Medication Adherence: To Take or Not to Take…That is the Problem
Jun 28: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Jun 29: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415